Compare Stocks: OMER, CGON, ERAS, and MIRM

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGON CG Oncology	$59.85 -3.2%	$72.27	$35.80 ▼ $80.97	$5.31B	0.28	1.12 million shs	1.08 million shs
ERAS Erasca	$13.39 -10.0%	$16.15	$2.11 ▼ $24.28	$4.68B	0.61	5.44 million shs	7.09 million shs
MIRM Mirum Pharmaceuticals	$80.14 -2.7%	$93.05	$63.23 ▼ $130.00	$5.20B	0.61	926,638 shs	462,924 shs
OMER Omeros	$16.20 -13.8%	$18.41	$6.24 ▼ $21.24	$1.17B	2.57	1.21 million shs	3.96 million shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGON CG Oncology	0.00%	-6.22%	-20.85%	-16.70%	+39.02%
ERAS Erasca	0.00%	-16.47%	-12.71%	-30.15%	+437.75%
MIRM Mirum Pharmaceuticals	0.00%	-6.82%	-18.90%	-32.58%	+5.18%
OMER Omeros	0.00%	-18.31%	-12.20%	+67.18%	+55.47%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGON CG Oncology	$59.85 -3.2%	$72.27	$35.80 ▼ $80.97	$5.31B	0.28	1.12 million shs	1.08 million shs
ERAS Erasca	$13.39 -10.0%	$16.15	$2.11 ▼ $24.28	$4.68B	0.61	5.44 million shs	7.09 million shs
MIRM Mirum Pharmaceuticals	$80.14 -2.7%	$93.05	$63.23 ▼ $130.00	$5.20B	0.61	926,638 shs	462,924 shs
OMER Omeros	$16.20 -13.8%	$18.41	$6.24 ▼ $21.24	$1.17B	2.57	1.21 million shs	3.96 million shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGON CG Oncology	0.00%	-6.22%	-20.85%	-16.70%	+39.02%
ERAS Erasca	0.00%	-16.47%	-12.71%	-30.15%	+437.75%
MIRM Mirum Pharmaceuticals	0.00%	-6.82%	-18.90%	-32.58%	+5.18%
OMER Omeros	0.00%	-18.31%	-12.20%	+67.18%	+55.47%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CGON CG Oncology	2.70	Moderate Buy	$87.50	46.20% Upside
ERAS Erasca	2.64	Moderate Buy	$22.09	64.98% Upside
MIRM Mirum Pharmaceuticals	2.93	Moderate Buy	$147.88	84.52% Upside
OMER Omeros	2.60	Moderate Buy	$30.33	87.24% Upside

Current Analyst Ratings Breakdown

Latest OMER, CGON, ERAS, and MIRM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/15/2026	CGON CG Oncology	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/14/2026	MIRM Mirum Pharmaceuticals	Stifel Nicolaus Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$136.00 ➝ $156.00
10/14/2026	OMER Omeros	Cantor Fitzgerald Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Overweight	$22.00
10/13/2026	MIRM Mirum Pharmaceuticals	Evercore Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Outperform	$146.00
10/12/2026	MIRM Mirum Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Overweight	$137.00 ➝ $152.00
10/12/2026	MIRM Mirum Pharmaceuticals	TD Cowen Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
10/12/2026	MIRM Mirum Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$160.00 ➝ $184.00
10/12/2026	MIRM Mirum Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$195.00 ➝ $200.00
10/8/2026	OMER Omeros	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold (C-) ➝ Hold (C)
10/8/2026	MIRM Mirum Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Outperform	$135.00 ➝ $155.00
9/29/2026	MIRM Mirum Pharmaceuticals	Robert W. Baird Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Outperform	$123.00 ➝ $130.00

(Data available from 10/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CGON CG Oncology	$4.04M	1,313.14	N/A	N/A	$9.33 per share	6.41
ERAS Erasca	N/A	N/A	N/A	N/A	$1.05 per share	N/A
MIRM Mirum Pharmaceuticals	$521.31M	9.98	$0.05 per share	1,572.02	$6.12 per share	13.09
OMER Omeros	N/A	N/A	$1.87 per share	8.66	($1.71) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CGON CG Oncology	-$160.99M	-$2.69	N/A	N/A	N/A	-3,602.68%	-25.20%	-23.98%	11/13/2026 (Estimated)
ERAS Erasca	-$124.55M	-$0.95	N/A	N/A	N/A	N/A	-38.43%	-32.05%	11/11/2026 (Estimated)
MIRM Mirum Pharmaceuticals	-$23.36M	-$14.55	N/A	N/A	N/A	-139.18%	-36.28%	-8.54%	11/3/2026 (Estimated)
OMER Omeros	-$3.35M	$1.28	12.66	13.39	N/A	N/A	-164.92%	69.41%	11/12/2026 (Estimated)

Latest OMER, CGON, ERAS, and MIRM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/13/2026	Q3 2026	CGON CG Oncology	-$0.8341	N/A	N/A	N/A	$0.55 million	N/A
11/12/2026	Q3 2026	OMER Omeros	$0.03	N/A	N/A	N/A	$37.28 million	N/A
11/11/2026	Q3 2026	ERAS Erasca	-$0.1301	N/A	N/A	N/A	N/A	N/A
11/3/2026	Q3 2026	MIRM Mirum Pharmaceuticals	-$0.4873	N/A	N/A	N/A	$178.06 million	N/A
8/12/2026	Q2 2026	OMER Omeros	-$0.2683	$0.02	+$0.2883	$0.15	$12.69 million	$28.53 million
8/11/2026	Q2 2026	ERAS Erasca	-$0.1114	-$0.14	-$0.0286	-$0.14	N/A	N/A
8/6/2026	Q2 2026	CGON CG Oncology	-$0.6642	-$0.90	-$0.2359	-$0.90	$0.36 million	$1.16 million
8/5/2026	Q2 2026	MIRM Mirum Pharmaceuticals	-$0.7425	-$1.06	-$0.3175	-$1.06	$166.33 million	$176.24 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CGON CG Oncology	N/A	N/A	N/A	N/A	N/A
ERAS Erasca	N/A	N/A	N/A	N/A	N/A
MIRM Mirum Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
OMER Omeros	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CGON CG Oncology	N/A	22.22	22.20
ERAS Erasca	N/A	8.29	8.29
MIRM Mirum Pharmaceuticals	1.28	2.86	2.74
OMER Omeros	N/A	1.95	1.94

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CGON CG Oncology	26.56%
ERAS Erasca	67.78%
MIRM Mirum Pharmaceuticals	N/A
OMER Omeros	48.79%

Insider Ownership

Company	Insider Ownership
CGON CG Oncology	4.80%
ERAS Erasca	14.20%
MIRM Mirum Pharmaceuticals	8.32%
OMER Omeros	10.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CGON CG Oncology	142	88.64 million	84.39 million	Optionable
ERAS Erasca	103	349.76 million	300.10 million	Optionable
MIRM Mirum Pharmaceuticals	433	64.93 million	59.53 million	Optionable
OMER Omeros	175	72.39 million	64.79 million	Optionable

OMER, CGON, ERAS, and MIRM Headlines

Recent News About These Companies

Omeros stock fell 13.78 percent on Nasdaq on October 16, 23.70 percent below its high

44 minutes ago | ad-hoc-news.deA

Omeros shares fall 4% as European regulators uphold negative opinion on Narsoplimab

October 17 at 5:18 PM | msn.com

Omeros Stock Falls 12% After EMA Committee Reaffirms Negative Narsoplimab Opinion

October 17 at 12:17 PM | rttnews.com

Update: Omeros Shares Fall After Narsoplimab Application Rejected Again by EU Agency

October 16 at 6:55 PM | finance.yahoo.com

Omeros shares slide after CHMP upholds negative opinion on drug; analyst sees buying opportunity at $16

October 16 at 6:55 PM | msn.com

Omeros Says European Medicines Agency Upholds Negative Opinion on Narsoplimab Application -- Update

October 16 at 6:55 PM | marketwatch.com

Omeros (NASDAQ:OMER) Shares Gap Down - Should You Sell?

October 16 at 11:39 AM | marketbeat.com

Omeros: CHMP Issues Negative Opinion On Marketing Authorization Application For Narsoplimab

October 16 at 8:54 AM | rttnews.com

Omeros Narsoplimab Application Rejected Again by EU Medicines Committee

October 16 at 8:54 AM | finance.yahoo.com

Omeros shares slide following European regulatory setback for Narsoplimab

October 16 at 8:54 AM | finance.yahoo.com

Omeros Says European Medicines Agency Upholds Negative Opinion on Narsoplimab Application

October 16 at 8:54 AM | marketwatch.com

Omeros Receives Second CHMP Rejection For Narsoplimab In Europe; Stock Down

October 16 at 8:54 AM | rttnews.com

Omeros faces second rejection of narsoplimab in Europe – OMER stock falls below key support for first time in nearly 3 months

October 16 at 8:54 AM | msn.com

Omeros Stock Sinks on Negative EU Opinion for Narsoplimab, Compassionate-Use Program Ends

October 16 at 7:11 AM | benzinga.com

Omeros Corporation Receives CHMP Negative Opinion Following Re-Examination of European Marketing Authorization Application for Narsoplimab in TA-TMA

October 16 at 6:19 AM | businesswire.com

Omeros (NASDAQ:OMER) Earns "Overweight" Rating from Cantor Fitzgerald

October 16 at 2:23 AM | americanbankingnews.com

Omeros (NASDAQ:OMER) Stock Keeps "Overweight" Rating at Cantor Fitzgerald

October 14, 2026 | marketbeat.com

Omeros (NASDAQ:OMER) Stock Price Breaks Above 200 Day Moving Average - Here's What Happened

October 13, 2026 | marketbeat.com

Cantor Fitzgerald upgraded Omeros to Overweight for Omeros stock

October 8, 2026 | ad-hoc-news.deA

Omeros Corporation (NASDAQ:OMER) Stock Has Consensus Target Price of $34.00

October 4, 2026 | marketbeat.com

Omeros consensus price target cut by 16.67% to $37.40

October 3, 2026 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

OMER, CGON, ERAS, and MIRM Company Descriptions

CG Oncology NASDAQ:CGON

$59.85 -2.01 (-3.25%)

Closing price 10/16/2026 04:00 PM Eastern

Extended Trading

$59.83 -0.02 (-0.03%)

As of 10/16/2026 07:31 PM Eastern

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

Erasca NASDAQ:ERAS

$13.39 -1.48 (-9.95%)

Closing price 10/16/2026 04:00 PM Eastern

Extended Trading

$13.40 +0.01 (+0.07%)

As of 10/16/2026 07:56 PM Eastern

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Mirum Pharmaceuticals NASDAQ:MIRM

$80.14 -2.25 (-2.73%)

Closing price 10/16/2026 04:00 PM Eastern

Extended Trading

$80.81 +0.67 (+0.83%)

As of 10/16/2026 07:30 PM Eastern

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.

Omeros NASDAQ:OMER

$16.20 -2.59 (-13.78%)

Closing price 10/16/2026 04:00 PM Eastern

Extended Trading

$16.30 +0.10 (+0.62%)

As of 10/16/2026 07:49 PM Eastern

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest OMER, CGON, ERAS, and MIRM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest OMER, CGON, ERAS, and MIRM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

OMER, CGON, ERAS, and MIRM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

OMER, CGON, ERAS, and MIRM Company Descriptions

CG Oncology NASDAQ:CGON

Erasca NASDAQ:ERAS

Mirum Pharmaceuticals NASDAQ:MIRM

Omeros NASDAQ:OMER

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest OMER, CGON, ERAS, and MIRM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest OMER, CGON, ERAS, and MIRM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

OMER, CGON, ERAS, and MIRM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

OMER, CGON, ERAS, and MIRM Company Descriptions

CG Oncology NASDAQ:CGON

Erasca NASDAQ:ERAS

Mirum Pharmaceuticals NASDAQ:MIRM

Omeros NASDAQ:OMER

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools